Skip to main content
Equibles
ONC logo

ONC · BeOne Medicines Ltd.

Track ONC — free

Use ONC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ONC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$347.48 -8.53 (-2.40%) At close · Aug 14
Market Cap
$513.62B
Shares
1.48B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$347.48 Open$350.55 Day$343.50–352.51 52W close$260.27–377.47 Avg vol 30d405K Short int881K · 0.1% float · 2.4d Short vol29% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 15, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +10%
      above
      Price vs 50-day avg +14%
      above
      RSI (14) 64
      neutral
      MACD trend Positive
      52-week position 74%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Neutral
      1-month return +11%
      trailing
      6-month return −6%
      trailing
      YTD return +14%
      this year
      Relative strength −20%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $304 › 200d $315 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +46 funds added
      Insider flow Distributing
      Net -$8.2M over 90 days · 100% sells
      Short interest Falling
      0.06% of float · ▼ -5.0% MoM · 2.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      281 holders — mid 3-yr range
      Squeeze score 32
      low risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +22179%
      Y/Y
      Gross margin 1961%
      contracting
      EPS growth +140%
      Y/Y
      Free cash flow $941.7M
      Valuation P/E 789.7
      rich
      Balance sheet $3.5B
      net cash
      Quant / Vol
      risk profile
      Moderate
      Volatility 40%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 2.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 5, 2026
      Total revenue · Full Year 2026 $6.6B – $6.8B
      GAAP operating income · Full Year 2026 $1B – $1.1B
      GAAP operating expenses (combined R&D and SG&A) · Full Year 2026 $4.8B – $5B
      Non-GAAP operating income · Full Year 2026 $1.7B – $1.8B
      Other income (expense) · Full Year 2026 $-50M – $-25M
      Prior guidance period ended · from the 8-K filed Nov 6, 2025
      Total Revenue · Full Year 2025 $5.1B – $5.3B
      GAAP Operating Expenses (R&D and SG&A) · Full Year 2025 $4.1B – $4.3B
      Guided vs delivered · last 1 settled
      Total Revenue Full Year 2025
      guided $5.1B – $5.3B
      $5.34B Beat +2.8%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +10% Bullish
      Price vs 50-day avg
      +14% Bullish
      RSI (14)
      64 Neutral
      MACD trend
      Positive Bullish
      52-week position
      74% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $304 › 200d $315 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +46 funds added
      Insider flow Distributing
      Net -$8.2M over 90 days · 100% sells
      Short interest Falling
      0.06% of float · ▼ -5.0% MoM · 2.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      281 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $260 Now $347 · 74% Range high $377
      vs 200-day avg +10% vs 50-day avg +14%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted net income non-GAAP $819.54M Six Months Ended June 30, 2026 —
      Free Cash Flow non-GAAP $595.89M Six Months Ended June 30, 2026 —
      Adjusted net income (loss) non-GAAP $917.6M full year —
      GAAP → non-GAAP reconciliation
      GAAP GAAP net income (loss) 286.93M
      +510.25M Share-based compensation expenses
      +131.62M Depreciation
      +10.07M Amortization of intangibles
      +893K Other
      +75.63M Impairment of equity investments
      +24.78M Discrete tax items
      -122.56M Income tax effect of non-GAAP adjustments
      = Adjusted net income (loss) 917.6M
      Gross Margin as a percentage of global product sales (Adjusted) non-GAAP 87.8% full year —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ONC
      BeOne Medicines Ltd.
      this stock
      		$513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.69B +1.2% — — 2.1%
      CSLLY
      Csl Ltd
      		 $46.19B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      281
      % held
      2.4%
      Net QoQ
      +85.3K sh
      Top holder
      BAKER BROS. ADVISORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      129
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      880.6K
      Days to cover
      2.4d
      Change
      -46.4K sh
      View
      Short Volume
      Short vol %
      29%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      440
      Value
      $133.7K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      47.1%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$8.2M
      Buyers / Sellers
      0 / 11
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $5.3B
      Net income (FY)
      $286.9M
      EPS diluted
      $0.19
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 5, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $718.7K
      Shares
      2.0K
      Filed
      Aug 11, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ONC -0.2% +11.4% -6.3% +10.0% +14.4%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -0.6% +6.9% -20.0% +6.0% +0.5%
      Key facts CIK 1651308 CUSIP 07725L102 13F (30d) 288 filings 263 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)